Aiping Zhou

机构：Northwestern University, Chinese Academy of Medical Sciences & Peking Union Medical College, Government of Jiangsu Province, National Cancer Center, Fosun Pharma (China), Nanjing Drum Tower Hospital, Second Affiliated Hospital of Nanjing Medical University, OriginWater (China), Nanjing Medical University · ORCID：0000-0003-1632-837X

发表论文 138 篇 · 总被引 1664 次 · h-index 21

代表论文

• Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study (2023 · Annals of Oncology · 被引 79)
• Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer (2025 · New England Journal of Medicine · 被引 78)
• Combatting resistance: Understanding multi-drug resistant pathogens in intensive care units (2023 · Biomedicine & Pharmacotherapy · 被引 77)
• Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial (2024 · Gastric Cancer · 被引 22)
• First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial (2025 · The Lancet Oncology · 被引 10)
• Neutrophil extracellular traps in relationship to efficacy of systemic therapy for metastatic renal cell carcinoma (2023 · Cancer Medicine · 被引 8)